Cantor Fitzgerald Reiterates Overweight Rating, $5 on PAVmed (PAVM), "Encourage Investors to Acquire PAVM Shares at Attractive Valuation"
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $5.00 price target on PAVmed (NASDAQ: PAVM), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
